about Idarucizumab approved as first reversal agent for novel oral anticoagulant dabigatran (aphanet.org)
There was no significant difference between dabigatran and rivaroxaban in length of stay. (ucsf.edu)
Warfarin users, who were older on average than the other patients and had more co-morbidities, were hospitalized an average of 2 days longer than dabigatran users and 2.6 days longer than rivaroxaban users. (ucsf.edu)